Fertility experts

We know how important it is to be cared for by experienced specialists when treating fertility problems. When time is of the essence, it is worth putting your trust in a team of experts who will strive to ensure the treatment is as effective as possible.

blank
blank

Why can we help you effectively at INVICTA Clinics?

blank

We are experts

Over 60 per cent of patients come to us with ‘difficult cases’. For example, following unsuccessful treatment attempts at other centres, or with genetic issues, implantation disorders or co-morbidities. Amongst our patients, we are known as experts in special cases. Where does our strength lie? In our multidisciplinary team of specialists, who consult with one another as needed and find solutions. We are able to help both when simple steps are sufficient and when targeted, expert methods are required.

blank

We are shaping the future of medicine

We keep abreast of trends in medicine and develop innovative solutions to maximise treatment effectiveness by every percentage point. It was at the INVICTA Research and Development Centre that we decided to optimise the in vitro procedure and developed the AIOO® software and the world’s only Genetic Prediction of Stimulation (GPS™) test. By harnessing the potential of artificial intelligence and advances in genetics, we have developed solutions that make hormonal stimulation more effective, safer and more comfortable for patients.

blank

We are determined

At INVICTA Clinics, we keep searching for solutions until we find the right one. Our teams of doctors and diagnosticians work closely together to identify the cause of the problem as accurately as possible and to offer patients the best possible solutions. If a patient’s medical history requires it, we convene multidisciplinary medical consultations. Under the care of our specialists, you can be sure that we will do everything in our power to help you effectively. We approach each case individually and, every time, put in our utmost effort to ensure that treatment achieves the outcome our patients expect.

blank

We communicate transparently

At INVICTA Clinics, we speak in plain language. We want to ensure that each of our patients understands the treatment options we can offer them, the possible outcomes and the chances of success. We make sure there’s room for honest and open discussion, so that patients feel we’ve given them the information they need to make an informed decision that’s best for them. We present our services with no hidden costs, but with a range of options and packages so that everyone can choose the best option for themselves.

blank

We believe in the power of relationships

At INVICTA Clinics, everything starts with a partnership-based approach. We believe that we are most effective as a team, which is why we work together as partners. We believe that by treating the patient as a partner, we have the best chance of achieving our goal together. That is why, at our clinics, you can count on the support of a dedicated care coordinator and your attending doctor throughout the entire treatment process. We will ensure that you don’t miss anything, explain anything that proves difficult, and offer support whenever needed. We won’t simply present you with the facts; we’ll make you part of the process.

blank

We prioritise safety

We take an uncompromising approach to security. We use proprietary systems to secure medical data and monitor them in-house. We hold ISO quality accreditations and certificates. We participate in external audits to ensure that each of our processes is carried out to the highest standard. We implement proprietary solutions to ensure that the treatment process is safe and comfortable for patients. One such solution, the AIOO® software, has enabled us to reduce the dose of medication administered to patients during the hormonal stimulation phase by 10 per cent.

blank

We provide comprehensive care

We operate as a holistic healthcare centre. We carry out both basic and advanced tests in our own Medical Diagnostic Laboratories. We have a team of laboratory diagnosticians and doctors specialising in a range of fields (including gynaecologists, endocrinologists, geneticists, oncologists and embryologists), meaning that patients can have all their tests and specialist consultations carried out in one place. We operate using our own internal systems, ensuring that each of our doctors has access to patients’ medical records, and that patients do not need to worry about keeping track of their test results.

blank

We plan treatment to suit the patient’s convenience

Thanks to standardised care, a unified medical system and our commitment to quality, we enable patients to continue their treatment at any of our clinics. We maximise the opportunities for online contact. All appointments that do not require a physical visit to the INVICTA Clinic can be carried out remotely. These include consultations with a doctor, a patient care coordinator or a midwife, as well as appointments during which a doctor analyses ultrasound images. We also offer home-based tests, allowing samples to be collected at home. We upload consultation recommendations, test results and prescriptions to a system to which patients have 24/7 online access. We send reminders about when to take medication and when to attend the clinic. We strive to ensure that treatment is convenient and accessible for patients, regardless of where they live.

blank

We act with others in mind

As experts in fertility and the health of women and men, we feel a duty to use our expertise to educate and support initiatives aimed at promoting health in the broadest sense. One issue of particular importance to us is fertility preservation. We are keen to ensure that patients battling cancer know that they can preserve their gametes and give themselves the chance to become parents once their treatment is complete. People aged 21 or under who are suffering from cancer can preserve and store their gametes free of charge at the INVICTA Bank before starting treatment.

We share information about fertility

    • Liss J, Kunicki M, Czyzyk A, Pastuszek E, Zabielska J, Meczekalski B, Lukaszuk K, Clinical Utility of Different Anti-Müllerian Hormone (AMH) Assays for the Purpose of Pregnancy Prediction, Gynaecological Endocrinology 2017 (accepted for publication)
    • Pastuszek E, Lukaszuk A, Kunicki M, Mockun J, Kloss G, Malinowska I, Czyzyk A, Meczekalski B, Lukaszuk K, New AMH assay allows rapid point-of-care measurements of ovarian reserve, Gynaecological Endocrinology 2017 (accepted for publication)
    • Pastuszek E, Kiewisz J, Skowronska P, Liss J, Lukaszuk M, Bruszczynska A, Jakiel G, Lukaszuk K, An investigation of the potential effect of sperm nuclear vacuoles in human spermatozoa on DNA fragmentation using a neutral and alkaline Comet assay, March 2017;5(2):392–398, doi: 10.1111/andr.12324
    • Lukaszuk K, Pastuszek E, Samojedny A. Comment on: “Intracytoplasmic morphologically selected sperm injection (IMSI) does not improve outcome in patients with two successive IVF-ICSI failures” by Gatimel et al. J Assist Reprod Genet [Internet]. 2016; doi:10.1007/510815-016-0746-9
    • Meczekalski B, Czyzyk A, Kunicki M, Podfigurna-Stopa A, Plociennik L, Jakiel G, Maciejewska-Jeske M, Lukaszuk K. Fertility in women of late reproductive age: the role of serum anti-Müllerian hormone (AMH) levels in its assessment. J Endocrinol Invest. 14 June 2016. Epub ahead of print]”
    • Łukaszuk K., Jakiel G., Kuczynski W., Pukszta S., Liss J. Next-generation sequencing for pre-implantation genetic testing of blastocyst aneuploidies in women of different ages. 2016:23(1):163–6.
    • 17th World Congress on Human Reproduction, Rome, Italy (March 2017); Lecture: The role of genetic testing in recurrent pregnancy loss and recurrent implantation failure; Oral presentation of an abstract: New possibilities for point-of-care measurement using VIDAS – Anti-Müllerian hormone decline from the start of controlled ovarian stimulation to oocyte retrieval
    • PTMRiE and OSnPC specialist workshop ‘What’s new in ovulation induction and stimulation’ (January 2017); Lecture: Dynamics of AMH changes in stimulated cycles and natural cycles
    • 14th Congress of Obstetrics and Gynaecology of Ukraine, Kyiv, Ukraine (9/2017); Lecture: Clinical application of ovarian reserve assessment considering changing diagnostic possibilities
    • bioMérieux VIDAS AMH Workshop, Helsinki, Finland (July 2016); Lecture: Clinical needs in infertility management
    • 3rd International Conference on Reproductive Endocrinology, Warsaw, Poland (June 2016); Lecture: Hyperglycosylated hCG
    • Factors affecting male fertility. Current diagnostic and therapeutic methods in male infertility, Scientific Conference of the Andrology Section and the Fertility and Infertility Section of the Polish Gynaecological Society (June 2016), Łódź, Poland; Lecture: Genetic aspects of male infertility
    • CMKP certification course in Gynaecological Endocrinology and Reproduction – latest reports (May 2016), Poznań, Poland; Lectures: Children without defects – the development and future of pre-implantation diagnosis, and Genetic logic – the role of genetic counselling in the treatment of infertility, substantive and legal justifications
      Scientific conference: Gynaecological Endocrinology and Reproduction (5/2016), Kraków, Poland; Lecture: Recurrent miscarriages
    • Updates in Infertility Treatment (January 2016), Lisbon, Portugal; Lecture: Practical aspects of using AMH to adjust the dose for gonadotropin stimulation
      Lecture – Congress of the Polish Society of Reproductive Medicine and Embryology in Katowice (11/2015): Innovation for the Next Generations – Progress in Pre-implantation Genetic Diagnosis
    • Lecture – 32nd Congress of the Polish Gynaecological Society (September 2015) in Łódź: Personalised medicine based on available methods for assessing genetic predisposition
    • Lecture – Scientific Conference of the Pomeranian Bar Association on Medical and Pharmaceutical Law: In vitro from a doctor’s perspective – truths, myths, challenges
    • Lecture – 11th World Congress of the European Society of Gynaecology (ESG) in Prague (October 2015): Next-Generation Sequencing and new opportunities for Pre-implantation Genetic Diagnosis
    • Annual Conference of the Russian Society for Reproductive Medicine, Sochi, Russia (September 2015): Embryology pre-course: ‘Technical aspects of implementing next-generation sequencing in routine clinical practice’; main congress lecture: ‘Next-generation sequencing and new opportunities for pre-implantation genetic diagnosis’.
      European Human Genetics Conference 2015, Glasgow, UK (June 2015): Pre-implantation Genetic Testing Using Ion Torrent™ PGM™
    • Specialist Workshop organised by the Centre for Human Fertility Studies in Warsaw (June 2015): PGD/PGS – Polish experiences and ‘Menstrual cycle physiology and stimulation methods used in assisted reproduction’
    • Lecture for the Wrocław Branch of the Polish Gynaecological Society (April 2015): Clinical application of ovarian reserve assessment in the face of changing diagnostic capabilities
    • Workshop organised by the International Federation of Medical Students’ Associations (IFMSA-Poland) (1/2015): Infertility – a health scourge of the 21st century
    • Lecture for the Katowice Branch of the Polish Gynaecological Society (12/2014): The use of next-generation sequencing in pre-implantation genetic diagnosis (PGD-NGS)
    • Webinar (11/2014): Clinical application of ovarian reserve assessment in the face of changing diagnostic possibilities
    • Lecture for the Wrocław Branch of the Polish Gynaecological Society (October 2014): The use of next-generation sequencing in pre-implantation genetic diagnosis (PGD-NGS)
    • 7th Congress of the Polish Society of Human Genetics (September 2014): The use of next-generation sequencing (NGS) in pre-implantation genetic diagnosis (PGD)
    • 7th Congress of the Society for Reproductive Biology, Congress of the Polish Society for Reproductive Medicine (September 2014): Clinical application of ovarian reserve assessment in light of evolving diagnostic possibilities
    • Andrology Day of the Polish Society of Andrology (September 2014): PGD – Pre-implantation Genetic Diagnosis
    • OIL Olsztyn (February 2014): Presentation, Pre-implantation genetic diagnosis – a chance for a healthy child (February 2014)
    • Nordic Fertility Society 2014 (01/2014): Pre-implantation genetic diagnosis of HLA for X-linked immunoproliferative syndrome
    • Winter Forum 2013 (February 2013): AMH and Others – Practical Guidelines for Treatment Decisions
    • The use of mitochondrial transfer, nuclear transfer and pronuclear transfer in oocytes from women with mitochondrial diseases – KB-42/06 dated 28 June 2006.
    • Separation of sperm using annexin V, Hoechst 33342, the MSOME technique, HYPOOS, birefringence, infrared spectroscopy and Raman spectroscopy for in vitro fertilisation – Resolution No. 3/2011 of 31 March 2011
    • Assessment of ovarian reserve in women undergoing in vitro fertilisation – Resolution No. 4/2011 of 31 March 2011
    • Testicular tissue culture for subsequent freezing, sperm selection and autotransplantation in patients following chemotherapy – Resolution No. 21/2011 of 9 June 2011
    • Assessment of endometrial response and fertility following intrauterine administration of G-CSF – Resolution No. 32/2011 of 6 October 2011
    • Freezing of ovarian tissue – Resolution No. 31/2011 of 6 October 2011
    • Assessment of the ultrasound image of the female reproductive organs under physiological conditions and hormone levels during the various phases of the menstrual cycle – document no. KB – 5/13 dated 24 January 2013
    • The effect of the presence of anti-TPO antibodies on the success of in vitro fertilisation and embryo transfer – document no. KB – 9/13 dated 26 March 2013
    • The use of acupuncture in the treatment of infertility using assisted reproductive technologies – document no. KB – 10/13; it was concluded that this does not require the approval of the Bioethics Committee
    • Prenatal diagnosis in foetal cells from cervical smears using PLNGS – document no. KB – 10/13 dated 14 May 2013
    • Assessment of patients’ fertility based on levels of vitamin D and other fat-soluble vitamins in follicular fluid and plasma – document no. KB 12/13 dated 7 May 2013
    • Use of a non-invasive prenatal test to detect the risk of trisomy of chromosomes 21, 18 and 13 and quantitative abnormalities of chromosomes X and Y in the foetus – document no. KB 11/13 dated May 2013
    • The use of microfluidic systems in sperm isolation – document no. KB 14/13 dated 14 May 2013
    • Does in vitro fertilisation affect the process of X chromosome inactivation in humans – letter dated 19 April 2011 – no objection to the study.
    • Assessment of the relationship between ovarian reserve and fertility in women over 39 years of age depending on the levels of unsaturated fatty acids and fat-soluble vitamins – Resolution No. 39/2013
    • In vitro activation of human oocytes using calcium ionophores – Resolution No. 2/2014
    • The use of a non-invasive prenatal test to detect the risk of trisomy of chromosomes 21, 18 and 13 and quantitative abnormalities of chromosomes X and Y in the foetus – KB-8/14 of 9 April 2014
    • The use of next-generation sequencing for pre-implantation genetic diagnosis of blastomeres obtained from 3-day-old embryos in fresh transfer – KB-11/14 dated 20 May 2014
    • The impact of pre-implantation genetic diagnosis using next-generation sequencing on the pregnancy rate in frozen blastocyst-stage embryo transfers – KB-12/14 dated 20 May 2014
    • Assessment of the degree of sperm DNA fragmentation – a comparison of two methods: TUNEL and the comet assay – KB-13/14 dated 20 May 2014
    • Analysis of in vitro fertilisation (IVF) success rates and anti-Müllerian hormone concentrations in couples undergoing their first IVF cycle, by place of residence – KB 16/14 dated 12 June 2014- statistical, observational study; does not require KB approval
    • Assessment of the usefulness of measuring dehydroepiandrosterone sulphate (DHEAS) concentrations in predicting the outcomes of the first in vitro fertilisation (IVF) cycle in women undergoing a long stimulation protocol – KB-17/14 dated 12 June 2014 – observational study; does not require KB approval
    • Assessment of methods of contraception used, sexual behaviour and serum vitamin D levels in the population of the Pomeranian Voivodeship – NKBBN/325/2014 dated 28 October 2014
    • Assessment of the efficacy of luteal phase supplementation in patients undergoing in vitro fertilisation – an observational, randomised study – KB-6/15 dated 5 March 2015
    • Assessment of the prevalence of aneuploidy in 5-day-old embryos through genetic analysis of blastocyst fluid using next-generation sequencing – NKBBN/371/2015 dated 1 December 2015
    • Assessment of the prevalence of aneuploidy through the analysis of oocytes and polar bodies using next-generation sequencing – NKBBN/372/2015 dated 1 December 2015
    • Vitamin B12 deficiency and polymorphisms in genes associated with folate metabolism in the aetiology of recurrent miscarriages – NKBBN/405/2015 dated 1 December 2015
    • Analysis of polymorphisms in selected genes influencing reproductive characteristics in women treated for endocrine and idiopathic infertility – NKBBN/410/2015 dated 1 December 2015
    • Assessment of the effect of treatment with testosterone and dehydroepiandrosterone (DHEA) on the outcomes of in vitro fertilisation (IVF/ICSI) in women with diminished ovarian reserve – NKBBN/19/2016 dated 24 February 2016
    • Evaluation of the outcomes of ovulation stimulation using letrozole for in vitro fertilisation – NKBBN/226/2016

We are committed to providing high-quality care

    • We monitor the processes that affect the quality of the services we provide to ensure that the client’s requirements are met at every stage of service delivery
    • We listen to the ‘voice of the customer’ – all feedback we receive from customers is thoroughly analysed so that we can tailor our services to their needs as effectively as possible
    • We effectively manage the processes that affect the quality of the services we provide
    • INVICTA Clinic staff are committed to achieving customer satisfaction
    • We strive to continuously increase customer satisfaction through the ongoing improvement of the services we offer
    • We respond effectively to customers’ requests.
    • We ensure that the services we offer comply with the relevant regulations
    • We provide competent staff who understand the importance of customer requirements
    • We ensure effective communication
    • We ensure an efficient complaints-handling procedure
    • We guarantee that all the services we provide are carried out in the most environmentally friendly way possible
  • Accreditation certificate for Medical Laboratory AM 007, confirming compliance with the requirements of the standard: PN-EN ISO 15189 Medical laboratories. Requirements for quality and competence

    All medical laboratories must meet legal requirements and operate in accordance with good laboratory practice, but not every laboratory takes on the challenge of achieving accreditation in accordance with the PN-EN ISO 15189 standard, which confirms compliance with additional requirements regarding quality and technical competence.

    What are the benefits of accreditation?

    Undergoing accreditation introduces quality management into a medical laboratory as a systematic process, encompassing the supervision of all processes, procedures, staff qualifications and competences, and the working environment. During their audits, independent auditors from the Polish Centre for Accreditation confirm that the laboratory operates in accordance with best practice and provides medical laboratory diagnostic services of the highest standard.

    There are nearly 2,700 medical laboratories operating in Poland, of which only 14 are currently accredited; since 2013, INVICTA Medical Diagnostic Laboratories have been among the accredited laboratories. Worldwide, there are 8,700 accredited medical laboratories – as one of them, we confirm the world-class quality of our tests (as at 14 February 2022).

    In 2020, our scope of accreditation changed to a flexible one. This allows our laboratory to incorporate additional analyses and modify methods within the scope of accredited tests without having to notify the PCA. Obtaining this flexible scope is therefore a sign of the PCA’s utmost confidence in the operations of INVICTA Medical Diagnostic Laboratories.

    Our laboratories are accredited. What exactly does this mean for patients?

    • We listen to our clients, striving to meet their needs and expectations
    • We provide accurate information, ensuring the highest quality of our services and, above all, the reliability of test results
    • We operate on the basis of risk analysis with regard to patient safety
    • We monitor our work using quality indicators
    • We collect and analyse data from various sources to continuously improve our work

    Certificates and attestations confirming participation in interlaboratory quality control programmes

    In addition to our daily in-house quality control system, INVICTA Medical Diagnostic Laboratories participate in mandatory quality control schemes organised by Polish organisations:

    • the Central Centre for Quality Assessment in Laboratory Diagnostics in Łódź
    • Central Centre for Quality Assessment in Microbiology (Polmicro) in Warsaw

    INVICTA Medical Diagnostic Laboratories also participate in 50 additional international programmes run by, amongst others:

    • Randox – RIQAS programmes, England
    • Labquality, Finland
    • Instand, Germany
    • CFNetwork – Cystic Fibrosis European Network, Belgium
    • EMQN – European Molecular Genetics Quality Network, England
    • Cytogenetic European Quality Assessment, England
  • Fertility Excellence is a unique model of care designed to improve the effectiveness and accessibility of specialist treatment for patients. It involves a personalised approach to each couple’s specific issues, whilst optimising the costs associated with diagnosis and treatment.

    The Fertility Excellence model was developed on the basis of proven quality standards, recommendations from international medical associations and patient organisations, as well as data collected over many years from more than 2,000 patients and scientific analyses. In 2011, the programme based on Fertility Excellence was awarded the prestigious European Medal for Services by the Business Centre Club.

    The Fertility Excellence model offers:

    • the ability to estimate the effectiveness of treatment and establish a financial framework for it, even before a couple begins treatment
    • the selection of additional procedures, diagnostic methods and systemic solutions to enhance the effectiveness of treatment for patients who have not always been able to be helped in the past
    • a significant increase in the pregnancy success rate – averaging as high as 60%

    Thanks to advanced laboratory diagnostics and the results of the tests carried out, we are able to compare the predicted effectiveness of treatment with the costs incurred by the couple. This enables patients to make an informed decision about their treatment – fully aware of the opportunities and risks associated, amongst other things, with its effectiveness.

    Thanks to advanced laboratory diagnostics and our proprietary methodology for evaluating test results in the context of infertility treatment, certain stages of the process, such as hormonal stimulation, are planned in a more financially rational manner. This enables us to minimise the costs of treatment without compromising its effectiveness.

    The model is supported by modern IT solutions – including the INVICTUS system. This enables our medical team to manage each patient’s treatment process on an individual basis. The process is subject to rigorous standards and is constantly monitored – both in terms of diagnostics and the medical procedures employed.

  • ESHRE

    The INVICTA Clinic in Gdańsk is a member of the European Society of Human Reproduction and Embryology (ESHRE).

    This membership confirms that the INVICTA Clinic adheres to European standards in line with ESHRE requirements. INVICTA is a fully recognised centre for research into genetic defects in embryos and collaborates with the association.

    PTMRiE

    The INVICTA Clinic is a member of the Polish Society for Reproductive Medicine and Embryology (PTMRiE).

    Polish assisted reproduction centres that adhere to the PTMRiE’s recommendations and guidelines regarding the diagnosis and treatment of infertility, as well as the management of infertile couples, are invited to join the PTMRiE.

Certificates

blank

Diagnostics Excellence

blank

ISO 9001:2015 and ISO 14001:2015

We’re training

  • The continuing professional development programme for employees referred to in Article 60 of the Act of 25 June 2015 on the treatment of infertility, covering the collection, processing, testing and distribution of reproductive cells and embryos intended for use in medical assisted reproduction procedures, for persons whose activities directly affect the quality of reproductive cells and embryos, as well as the safety of donors and recipients.

  • The supplementary training programme for employees referred to in Article 60 of the Act of 25 June 2015 on the treatment of infertility, covering the collection, processing, storage, testing and distribution of reproductive cells and embryos intended for use in medically assisted reproduction procedures, for persons whose activities directly affect the quality of reproductive cells and embryos, as well as the safety of donors and recipients.